Overview

Effectiveness of Inactive Vitamin D Supplementation in Non-Alcoholic Fatty Liver Disease Patients

Status:
Recruiting

Trial end date:
2023-03-05

Target enrollment:
0

Participant gender:
All

Summary

Aim of work The aim of our study is to assess the effectiveness and safety of high oral loading dose of inactive vitamin D supplementation on the clinical parameters related to liver steatosis, glycaemic control, insulin resistance and metabolic profile in NAFLD patients

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Ain Shams University

Treatments:

Cholecalciferol
Vitamin D

Criteria

Inclusion Criteria:

- patients >18 years with fatty liver diagnosis by using upper abdominal ultrasound
echography (US)

- patients with T2D diagnosed according to ADA 2019 criteria and treated with metformin.

Exclusion Criteria:

- Pregnant and/or lactating women,

- excessive alcohol use (as defined by an average daily consumption of alcohol > 30
g/day in men and > 20 g/day women),

- patients with other causes of chronic liver disease as viral hepatitis, drug induced
hepatitis, autoimmune hepatitis, patients suffering of chronic kidney disease,
hyper/hypoparathyroidism,

- hypersensitivity to cholecalciferol,

- hypercalcemia,

- patients taking supplementation with vitamin D,

- calcium and medications affecting calcium/vitamin D metabolism (as: anticonvulsants,
glucocorticoids, antacids).